Pfizer

Participant's Lead

Project Staff

Company Presentation

Pfizer Oncology is committed to delivering the right drug to the right patient at the right time. Pfizer‘s biomarker and companion diagnostics strategy is aimed at improving confidence in efficacy by optimal cancer patient selection in clinical trials, as exemplified by crizotinib (PF-02341066), an inhibitor of c-MET and ALK tyrosine kinases which shows impressive activity in cells from Non-Small Cell Lung Cancer (NSCLC) containing EML4-ALK translocations, both in vitro and in NSCLC patients. The safety and efficacy of crizotinib is currently being assessed in phase 3 trials with advanced NSCLC having a translocation or inversion event (NCT00932893). Pfizer Oncology is committed to achieving similar success with its promising and extensive portfolio, in multiple tumor types towards first-in-class and best-in-class therapies to make meaningful improvements in the lives of cancer patients.